Navigation Links
Intrexon Announces Third Quarter Financial Results
Date:11/7/2013

this information to investors and others to assist them in understanding and evaluating our operating results in the same manner as our management and board of directors. While we believe that this non-GAAP financial measure is useful in evaluating our business, and may be of use to investors, this information should be considered as supplemental in nature and is not meant as a substitute for the related financial information prepared in accordance with GAAP. In addition, this non-GAAP financial measure may not be the same as non-GAAP financial measures presented by other companies.  Adjusted EBITDA is not a measure of financial performance under GAAP, and is not intended to represent cash flows from operations under GAAP and should not be used as an alternative to net income or loss as an indicator of operating performance or to represent cash flows from operating, investing or financing activities as a measure of liquidity.  We compensate for the limitations of Adjusted EBITDA by using it only to supplement our GAAP results to provide a more complete understanding of the factors and trends affecting our business.  Adjusted EBITDA has its limitations as an analytical tool and you should not consider it in isolation or as a substitute for analysis of our results as reported under GAAP.

In addition to the reasons stated above, which are generally applicable to each of the items we exclude from our non-GAAP financial measure, we believe it is appropriate to exclude certain items for the following reasons:

  • Interest expense may be subject to changes in interest rates which are beyond our control;
  • Depreciation of our property and equipment and amortization of acquired identifiable intangibles can be affected by the timing and magnitude of business combinations and capital asset purchases;
  • Stock-based compensation expense is a noncash expense and may vary significantly based on the timing, size and nature of awards grant
    '/>"/>

  • SOURCE Intrexon Corporation
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

    Related medicine technology :

    1. Soligenix and Intrexon Pursue Melioidosis Therapy Through Worldwide Exclusive Collaboration
    2. Misonix, Inc. Announces First Quarter Fiscal Year 2014 Financial Results
    3. Pro-Dex, Inc. Announces Fiscal 2014 First Quarter Financial Results Conference Call And Webcast
    4. DURECT Announces Proposed Public Offering of Common Stock
    5. Cellular Biomedicine Group Announces November 07, 2013 as Voting Deadline for Its Annual Shareholder Meeting
    6. Star Scientific Announces Leadership Transition, Acceleration of Plans for Submission of an IND to FDA for Pharmaceutical Version of Anatabine Compound
    7. Echo Therapeutics Announces Third Quarter 2013 Financial Results
    8. Regado Biosciences, Inc. Announces Third Quarter 2013 Results
    9. PDL BioPharma Announces Third Quarter 2013 Financial Results
    10. Regulus Announces Timing for Third Quarter 2013 Financial Results Webcast and Conference Call
    11. Heska Announces Financial Results for the Third Quarter of Fiscal 2013
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/31/2015)... 31, 2015 Quietly, sedately, Morocco,s ... the domestic pharmaceutical industry is strong, with a well-developed ... high international standards. One place where the ... sub-Saharan Africa: Morocco has quietly become the second largest ... Africa . Indeed, Moroccan pharma companies have been ...
    (Date:7/31/2015)... , July 31, 2015 ... Analyzers Market by Product (Bioimpedance Analyzers (BIA), Dual-Energy X-ray ... Hydrostatic Weighing) - Global Analysis & Forecast to 2019", ... was pegged at $911.1 Million 2014 and is estimated ... a CAGR of 9.4% from 2014 to 2019. ...
    (Date:7/30/2015)... , July 30, 2015 IRIDEX Corporation ... release its second quarter 2015 financial results after the ... In conjunction with the release, the Company will host ... 5:00 p.m. Eastern Time on Thursday, August ... quarter and other business developments. Interested parties ...
    Breaking Medicine Technology:PharmaBoardroom Releases New Morocco Pharmaceuticals Report 2PharmaBoardroom Releases New Morocco Pharmaceuticals Report 3Body Composition Analyzers Market Worth $1,425.7 Million by 2019 2Body Composition Analyzers Market Worth $1,425.7 Million by 2019 3Body Composition Analyzers Market Worth $1,425.7 Million by 2019 4IRIDEX Announces Second Quarter 2015 Conference Call and Release Date 2
    ... May 25, 2012  ... and Multilab Indústria e Comércio de Produtos Farmacêuticos ... jointly announced that both parties have signed an ... Brazil, "Takeda Brazil"), a wholly-owned subsidiary of Takeda, ...
    ... 2012  The National Organization for Rare Disorders (NORD) applauds legislation ... the Food and Drug Administration Safety & Innovation Act ... the most comprehensive improvements to public policy for rare disease ... . (Logo: http://photos.prnewswire.com/prnh/20110719/DC37656LOGO-b ) ...
    Cached Medicine Technology:Takeda to Acquire Multilab, Enhancing its Business Infrastructure in Brazil 2Takeda to Acquire Multilab, Enhancing its Business Infrastructure in Brazil 3Takeda to Acquire Multilab, Enhancing its Business Infrastructure in Brazil 4NORD Calls Senate Bill Most Important Since Orphan Drug Act 2
    (Date:7/31/2015)... ... July 31, 2015 , ... Precision Aesthetics is New York’s only Thermage ... also the first provider of Exilis non-surgical fat reduction in New York. Due ... attracted a large International clientele. Many patients travel to New York to get ...
    (Date:7/31/2015)... ... July 31, 2015 , ... The 2nd annual Ride to Fight On ... on October 3, 2015. The Ride to Fight On is a cycling fundraiser that ... Healthcare, The West Clinic and The University of Tennessee Health Science Center. A health ...
    (Date:7/31/2015)... ... 31, 2015 , ... Jacksonville-based drug and alcohol rehabilitation center, ... Center. The medical community, social workers, law enforcement, and government officials are all ... the effort to better understand and combat sex trafficking. Lead by sex trafficking ...
    (Date:7/31/2015)... ... July 31, 2015 , ... M3 USA MDLinx.com, source of the ... new Board Exam Courses. , The additions of Gastroenterology, Pulmonology and Allergy/Immunology round ... MDLinx makes preparing for the exam easy and painless. MDLinx offers thousands of ...
    (Date:7/31/2015)... ... July 31, 2015 , ... According to an ... gathered to see if they could reach a consensus on the steps that need ... facelifts. Overall, the group reached 90 percent consensus on a series of steps that ...
    Breaking Medicine News(10 mins):Health News:West Cancer Center Announces 2nd Annual Ride to Fight On 2Health News:West Cancer Center Announces 2nd Annual Ride to Fight On 3Health News:Lakeview Health Links Sex Trafficking and Addiction in Special Jacksonville Educational Workshop 2Health News:Lakeview Health Links Sex Trafficking and Addiction in Special Jacksonville Educational Workshop 3Health News:MDLinx Offers Three New Board Exam Prep Courses - Gastroenterology, Pulmonology and Allergy/Immunology 2Health News:MDLinx Offers Three New Board Exam Prep Courses - Gastroenterology, Pulmonology and Allergy/Immunology 3Health News:Article on Plastic Surgery Consensus Highlights the Duties of Veteran Plastic Surgeons, says Beverly Hills Physicians 2Health News:Article on Plastic Surgery Consensus Highlights the Duties of Veteran Plastic Surgeons, says Beverly Hills Physicians 3
    ... ... teach participants unique personal marketing strategies to find employment with a six-point system “The ... is a former talk show host in Columbia at WVOC 560 AM; Kenneth Shuler ... be held for Thomas providing free career counseling services , ...
    ... ... infection 33 times greater than that reported for our accredited ambulatory surgery centers. ... (PRWEB) June 18, ... Schaefer, Michael Jhung et al (JAMA 2010;303(22):2273 - 2279) correctly places emphasis on the ...
    ... disorder affecting one in 100 people worldwide. Most cases aren,t ... hallucinations as a teenager or adult. By that time, the ... difficult to treat. In a paper published recently online ... the University of North Carolina at Chapel Hill and Columbia ...
    ... The National Heart, Lung, and Blood Institute (NHLBI), part of ... to determine if the safety and efficacy of red blood ... been stored. One of the grants supports the first large, ... patients who receive transfusions of red blood cells that have ...
    ... ... to help women restore energy, passion and healthy hormonal balance. , ... Tampa, FL (Vocus) June 21, 2010 ... supplement for women. Dan-e™ is made of a patent-pending blend of Pro-Hormones and vital ...
    ... University of Leicester and the University of Ferrara in Italy ... to relieve cancer pain without causing many of the side ... show that 90% of cancer patients experience pain in the ... problem. Currently, the use of drugs like morphine produces side ...
    Cached Medicine News:Health News:Columbia Extreme Job Makeover Slated for June 26 2Health News:Columbia Extreme Job Makeover Slated for June 26 3Health News:Infection Rate in Accredited Ambulatory Facilities is Lower than in Hospitals 2Health News:Brain signs of schizophrenia found in babies 2Health News:NHLBI funds research to improve safety of red blood cell transfusions 2Health News:NHLBI funds research to improve safety of red blood cell transfusions 3Health News:NHLBI funds research to improve safety of red blood cell transfusions 4Health News:NHLBI funds research to improve safety of red blood cell transfusions 5Health News:NHLBI funds research to improve safety of red blood cell transfusions 6Health News:NHLBI funds research to improve safety of red blood cell transfusions 7Health News:World Renowned Physician Launches Dan-e™ All-Natural Nutritional Supplement for Women 2Health News:New drugs to relieve cancer pain 2
    ... D15/810 diode laser is a versatile and ... soft tissue applications. With excellent hemostatic and ... flexible fiber optic delivery system that allows ... environments alike.,Compact and portable, the Ceralas D15/810 ...
    ... II is a monoclonal antibody based ... identification of Neisseria gonorrhoeae. The test ... run with no heating or pretreatment. ... viable or fresh cultures. GonoGen&trade II ...
    The One-Step Gonorrhea Antigen Tests are qualitative immunoassays for detecting the Gonorrhea Antigen (NGH) in secretory products (swab)....
    ... thermal keratoplasty (LTK). This procedure was FDA ... reduction of hyperopia from +0.75 to +2.50 diopters ... to 0.75 diopters of astigmatism and refractive stability ... refractive surgery, LTK is not performed in an ...
    Medicine Products: